Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent

In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated expression and clinical relevance of programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1) and CD8 in tumors of 208 sarcoma patients. Primary untreated osteosarcoma (n = 46), Ewing sarcoma (n = 32...

Descripción completa

Detalles Bibliográficos
Autores principales: van Erp, Anke E.M., Versleijen-Jonkers, Yvonne M.H., Hillebrandt-Roeffen, Melissa H.S., van Houdt, Laurens, Gorris, Mark A.J., van Dam, Laura S., Mentzel, Thomas, Weidema, Marije E., Savci-Heijink, C. Dilara, Desar, Ingrid M.E., Merks, Hans H.M., van Noesel, Max M., Shipley, Janet, van der Graaf, Winette T.A., Flucke, Uta E., Meyer-Wentrup, Friederike A.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642642/
https://www.ncbi.nlm.nih.gov/pubmed/29050367
http://dx.doi.org/10.18632/oncotarget.19071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642642/
https://www.ncbi.nlm.nih.gov/pubmed/29050367
http://dx.doi.org/10.18632/oncotarget.19071

Ejemplares similares